1. Herishanu Y, Lishner M, Bornstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet. 128:154-7, 2001 2. Kitay-Cohen Y, Amiel A, Ashur Y, Fejgin MD, Herishanu Y, Afanasyev F, Bornstein Y, Lishner M. Analysis of chromosomal aberrations in large hepatocellular carcinomas by Comparative genomic hybridization.
Cancer Genet Cytogenet. 131:60-4, 2001 3.Amiel A, Elis A, Maimon O, Ellis M, Herishanu Y, Gaber E, Fejgin MD, Lishner M. Replication status in leukocytes of treated and untreated patients with polycythemia vera and essential thrombocytosis. Cancer Genet Cytogenet. 133:34-8, 2002
4. Herishanu Y, Lishner M, Kitay-Cohen Y. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs. 13:177-9, 2002
5.Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 70:329, 2002
6.Herishanu Y, Berliner S. Electronic blood cell counters are by no means perfect. Isr Med Assoc J. 4:1082-1083,2002.
7.Herishanu Y, Trestman S, Kigrner I, Rachmani R, Naparstek E. Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis. Leuk Lymphoma. 44:2103-8, 2003
8.Herishanu Y. Intensive therapy for aggressive lymphoma.N Engl J Med 351:99, 2004
9.Herishanu Y, Misgav M, Kigrner I, Ben-Tal O, Eldor A, Naparstek E.
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45:1407-1411, 2004 10.Herishanu Y, Kay S, Rogowski O, Pick M, Naparstek E, Deutsch V.R., Polliack A. T-cell ZAP-70 over-expression in chronic lymphocytic leukemia (CLL) correlates with CLL Cell ZAP-70 levels, clinical stage and disease progression.Leukemia. 19:1289-91, 2005
11. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thromboembolism following administration of intravenous immunoglobulins.
Blood Coagul Fibrinolysis. 16:313-8, 2005
12.Ben-Ami R, Paran D, Herishanu Y, Elkayam O, Shopin L. Venous and arterial thrombosis following administration of intravenous immunoglobulins: reply to Feuillet and colleagues. Blood Coagul Fibrinolysis. 16:619, 2005
13.Herishanu Y, Polliack A. Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options.Transfus Apheresis Sci. 32:85-97, 2005 14. Herishanu Y*, Kay S*, Pick M, Rogowski O, Baron S, Naparstek E, Polliack A and Deutsch VR. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome . Cytometry B Clin Cytom 70:218-226,2006.* these authors contributed equally to this work
15.Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, and Naparstek E.
Fatal interstitial pneumonitis related to Rituximab containing regimen. Clin Lymphoma Myeloma 6:407-409, 2006
16.Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U.
Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin`s Disease. Radiol Clin North Am 45:697-709,2007
b. PET Clinics 1(3), 2006. 17. Herishanu Y, Rogowski O, Polliack A and Marilus R. Leukocytosis in obese individuals, possible link in patients with unexplained persistent neutrophylia. Eur J Haematol 76: 516-520, 2006 2007
18. Herishanu Y*, Perry C*, Braunstein R, Metser U, Goor O, Rogowski O, Berliner S, Polliack A, Naparstek E Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin`s lymphoma. Eur J Haematol 79: 150-154, 2007
19. Herishanu Y*, Perry C*, Metser U, Bairey O, Rochlemer S, Trejo L, Naparstek E, Sapir E E, Polliack A. Diagnostic accuracy of PET/CT in patients with extranodal zone (MALT) lymphoma. Eur J Haematol 79: 205-209, 2007 * these authors contributed equally to this work
20.Herishanu Y, Wiestner A. Prognostic factors for risk-adapted therapy in chronic lymphocytic leukemia-The search continues. Leuk Lymphoma 48:1468-1469, 2007
21. Katz B-Z, Muhl L, Ilan N, Herishanu Y, Deutsch V, Naparstek E, Vlodavsky I, Preisner KT.Heparanase modulates heparinoids anticoagulant via non-enzymatic mechanisms. Tromb Haemost 98:1193-1199, 2007
22. Steinvil A, Berliner S, Herishanu Y, Paran Y, Justo D, Cohen M, Shapira I, Rogowski O. Range and determinants of white blood cell count in a large survey of Israelis without inflammation. IMAJ 6: 363-366, 2009
23. Rozovski U, Herishanu Y, Gipstein L, Naparstek E. fatal H1N1 influenza infection in an allogeneic SCT recipient. Bone Marrow Transplantation. 2010;45:1572-3
24. Herishanu Y, Eshel R, Kay S, Njuguna N, Rothman R, Perry C, Shpringer M,Wiestner A, Polliack A, Naparstek A. Unexpected detection of monoclonal B-cell lymphocytosis in a HLA-matched sibling donor on the day of allogeneic stem cell transplantation for a patient with chronic lymphocytic leukemia : Clinical outcome. Br J Haematol. 2010;149:905-7.
25. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire1 B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stettler-Stevenson M, Yuan C, Sherry R, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.The lymph node as the site of B-cell activation and tumor proliferation in chronic lymphocytic leukemia . Blood. 2011;117:563-74
26. Herishanu Y, Gibellini F, Njuguna N, Keyvanfar K, Wiestner A. CD44 signaling increases MCL-1 protein expression and protects CLL cells from spontaneous and fludarabine-induced apoptosis. Leuk Lymphoma. 2011 Sep;52(9):1758-69
27. Bairey O, Ruchlemer R, Rahimi-Levene N, Herishanu Y, Braester A, Berrebi A, Polliack A, Klepfish A, Shvidel L; Israeli CLL Study Group (ICLLSG). Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. Ann Hematol. 2011 May 26. [Epub ahead of print]
28. Ben-Baruch S, Canaani J, Braunstein Rony, Chava P, Ben-Ezra J, Polliack Aaron Naparstek, Elizabeth and Herishanu Y. The diagnostic role of bone marrow biopsy for fever of unknown origin in the modern era. Accepted Mayo Clinic Proceeding 2011
29. Shvidel Lev, Braester Andrei, Bairey Osnat, Rahimi-Levene Naomi, Klepfish Abraham, Herishanu Yair, Shtalrid Mordechai, Polliack Aaron and Berrebi Alain, for the Israeli CLL Study Group. Survival trends among 1,325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. Accpeted Americcan journal of Hematology 2001
30.Chava P, Hazan-Halevy I, Kay S, Golan T, Bdolach N, Herishanu Y, Naparstek E, Polliack A, Grisaru D. Reciprocal changes in regulatory T cells and Th17 helper cells can be skewed by exercise in patients with chronic lymphocytic leukaemia. Submitted 2010
31. Binsky-Ehrenreich I, Sobota M, Marom A, Lantner F, Harpaz N, Shvidel L, Berrebi A, Hazan-Halevy I, Haran M, Herishanu Y, Aloshin A, Sagi I, Goldenberg DM, Leng L, Bucala R and Shachar I. CD84 serves as a survival receptor in CLL cells. Submitted 2010
32. Herishanu Y, Kay S, Dezorella N, Baron S, Hazan-Halevy I, Trestman S, Perry C, Deutsch V, Polliack A, Naparstek E and Katz BZ. Intra-clonal diversity identified by CD19-mediated signaling correlates with disease progression in chronic lymphocytic leukemia. Submitted 2011.
33. Perry C, Hazan-Halevy I, Kay S, Deutsch V, Polliack A, Naparstek E and Herishanu Y. Increased CD39 expression on CD4+ T-lymphocytes has clinical and prognostic significance in chronic lymphocytic leukaemia. Submitted 2011
Book Authorship:
Herishanu Y, Perry C, Polliack A. Rituximab related Pulmonary Toxicity. Pulmonary Involvement in Patients with Hemtological Malignancies 2100. (Springer)
